Passage Bio
Business Services · Pennsylvania, United States · 58 Employees
View Company Info for Free
About
Headquarters
2005 Market St Fl 39, Philadelphia, Pennsylvani...Phone Number
(267) 866-0311Website
www.passagebio.comRevenue
$85.2 MillionStock Symbol
PASGIndustry
Highlights
$441.5M
Total Funding Amount
$216M
Most Recent Funding Amount
3
Number of Funding Rounds
Who is Passage Bio
Passage Bio Org Chart
Is Passage Bio your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Passage Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Passage Bio
Passage Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Passage Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Passage Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Passage Bio launches new products
Click to see if Passage Bio had a recent Job posting/layoffs
Check out if Passage Bio is spiking on competitors!
Recommended Actions
Find VP level buyers at Passage Bio
Find 2 more new buyers
Compare Similar Companies to Passage Bio
Compare insights from companies similar to Passage Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Passage Bio financials insights
Gather financial insights about Passage Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Passage Bio Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
Passage Bio Tech Stack
A closer look at the technologies used by Passage Bio
Most Recent Scoops
Passage Bio News & Media
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET.Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant)Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET.Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)
Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF progranulin levels were sustained up to 12 months post-treatment
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Passage Bio
Founded in 2017, Passage Bio is a genetic medicines company based in Philadelphia, PA that is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases.... Read More